Detalhe da pesquisa
1.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878237
2.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Cancer Sci
; 113(11): 3877-3887, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35792064
3.
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
JAMA Oncol
; 10(2): 185-192, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095881
4.
Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States.
Cancer Treat Res Commun
; 36: 100726, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37301127
5.
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
J Clin Oncol
; 41(36): 5505-5511, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37910822
6.
Reply to P.-H. Luo et al.
J Clin Oncol
; 42(13): 1596-1598, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452314